-- New Form Simplifies Enrollment for Shareholders with Shares in "Street Name" --

-- UNMC is 5th Site Open to Patient Enrollment for the Repair of Severe Leg Fractures Using Aastrom's Proprietary TRCs --

-- Enrollment Open for Repair of Severe Leg Fractures Using Company's Proprietary TRCs --

-- Enrollment Open for Repair of Severe Leg Fractures at Orthopedic Trauma Center Using Company's Adult Stem Cell Product --

-- Enrollment Open for Repair of Severe Leg Fractures Using Company's Proprietary TRCs at 4th Site --

ANN ARBOR, Mich., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has entered into a stock purchase agreement

Aastrom Biosciences Corrects Warrant Exercise Price Related to April 5, 2004 Sale of Common Stock Ann Arbor, Michigan, April 6, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that the exercise price of the warrants issued to a group of institutional investors was $1.65 per share

-- Expands Aastrom's Cell Production Products Business --

ANN ARBOR, Mich., March 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has completed a $40 million private

Headquarters moved to Cambridge, Mass.; New ticker symbol: VCEL